CurrentColorado Rocky Mountain Health PlansPolicy 2025 P 2286-5

Vtama (tapinarof) prior authorization / medical necessity

Defines prior authorization and medical necessity criteria for topical Vtama (tapinarof) for plaque psoriasis and atopic dermatitis, including initial and reauthorization rules and concurrent therapy exclusions for affected members.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyVtama (tapinarof) prior authorization / medical necessity

Policy CodePolicy 2025 P 2286-5

Change TypeMaterial coverage updates (added indicationrevised authorization rules)

Effective Date8/1/2025

Next Review Date

Key ActionSubmit prior authorization documenting diagnosis and required topical therapy trials (or reason for failure/intolerance) and confirm patient is not on a targeted immunomodulator.

SourceLink

POLICY UPDATE CHANGES

Added coverage criteria for atopic dermatitis.

Updated initial authorization length to 12 months.

Updated not to be used in combination with targeted immunomodulators.

Simplified reauthorization criteria to require documentation of positive clinical response and absence of combination with targeted immunomodulator.

Removed prescriber requirement.

2 indicationscovered conditions

12 monthsauthorization period

4 weeks

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Use of Vtama in combination with the targeted immunomodulators listed in this policy is excluded. Concurrent administration with these agents (examples include etanercept, certolizumab, golimumab, abatacept, adalimumab, ustekinumab, risankizumab, guselkumab, secukinumab, ixekizumab, brodalumab, tildrakizumab, tofacitinib, baricitinib, upadacitinib, apremilast, tralokinumab, abrocitinib, dupilumab) will result in non-coverage or denial unless the combination is specifically addressed by an alternative policy or clinical exception.

Initial Authorization Rules by Indication

Reauthorization and Continuation Rules

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization required. Initial approval is granted only when the diagnosis and documentation of required prior topical therapy trials are provided.

Initial authorization: Diagnosis of plaque psoriasis or atopic dermatitis must be documented.
Initial authorization: Documentation of a minimum 4-week trial (or history of failure, contraindication, or intolerance) of the required topical therapy per indication is required.
Authorization term: 12 months.

Step Therapy

Topical Therapy Trial Requirement

Requires prior trial and failure, contraindication, or intolerance to specified topical therapies/classes before initial approval. Trials must be appropriate to the severity and indication.

Plaque psoriasis: Minimum 4-week trial and failure, contraindication, or intolerance to one of the following: topical corticosteroids (e.g., betamethasone, clobetasol, desonide), vitamin D analogs (e.g., calcitriol, calcipotriene), tazarotene, calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), anthralin, or coal tar.
Atopic dermatitis: History of failure, contraindication, or intolerance to one of the following classes: for mild disease a topical corticosteroid (any potency, e.g., desonide, hydrocortisone); for moderate disease a medium- to high-potency topical corticosteroid (e.g., mometasone, fluocinonide); or a topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus).

Documentation Required

Reauthorization Documentation

For reauthorization, documentation of a positive clinical response to therapy and confirmation that the product is not being used in combination with excluded targeted immunomodulators is required.

Reauthorization criteria: Documentation of positive clinical response to Vtama.
Reauthorization term: Authorization will be issued for 12 months when criteria are met.

Denial Risk

Concurrent Targeted Immunomodulator Exclusion

Concurrent use of Vtama with specified targeted immunomodulators is excluded. Do not approve when the patient is receiving Vtama in combination with any listed targeted immunomodulator.

Excluded concurrent agents include, but are not limited to: etanercept (Enbrel), certolizumab (Cimzia), golimumab (Simponi), abatacept (Orencia), adalimumab, ustekinumab (Stelara), risankizumab (Skyrizi), guselkumab (Tremfya), secukinumab (Cosentyx), ixekizumab (Taltz), brodalumab (Siliq), tildrakizumab (Ilumya), tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), apremilast (Otezla), tralokinumab (Adbry), abrocitinib (Cibinqo), dupilumab (Dupixent).
Do not combine Vtama with other targeted immunomodulators; patient must not be receiving combination therapy for initial approval or reauthorization.

Coding and Trial Duration Details

Minimum topical trial duration for plaque psoriasis — 4-week trial

Minimum topical trial duration4-week trial required for plaque psoriasis prior to Vtama approval

Required trial outcomeMust demonstrate failure, contraindication, or intolerance to the topical therapy after the 4-week trial

Eligible topical classes/examplesCorticosteroids (e.g., betamethasone, clobetasol, desonide); Vitamin D analogs (e.g., calcitriol, calcipotriene); tazarotene; calcineurin inhibitors (e.g., tacrolimus, pimecrolimus); anthralin; coal tar

Step	Requirement	Notes
1	Prior trial and failure, contraindication, or intolerance to one appropriate topical therapy/class	For plaque psoriasis the prior topical trial must be a minimum of 4 weeks; examples include topical corticosteroids (e.g., betamethasone, clobetasol, desonide), vitamin D analogs (e.g., calcitriol, calcipotriene), tazarotene, calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), anthralin, or coal tar.
1	Prior trial and failure, contraindication, or intolerance to one appropriate topical therapy/class	For atopic dermatitis, history of failure/contraindication/intolerance to an appropriate topical therapy per severity: mild — any potency topical corticosteroid (e.g., desonide, hydrocortisone); moderate — medium- to high-potency topical corticosteroid (e.g., mometasone furoate, fluocinonide); or one topical calcineurin inhibitor (e.g., pimecrolimus, tacrolimus).

Drug and Term Definitions

Vtama (tapinarof) — drug definition and approved indications

Drug name & classVtama (tapinarof) — topical aryl hydrocarbon receptor agonist

IndicationsTopical treatment of plaque psoriasis in adults; topical treatment of atopic dermatitis in adults and pediatric patients ≥2 years

Concurrent therapy exclusionNot to be used in combination with targeted immunomodulators (multiple examples listed in policy)

Authorization notesPrior authorization required with indication-specific topical therapy trial requirements; initial and reauthorization approvals issued for 12 months when criteria met

Clinical Background

Vtama (tapinarof) is a topical aryl hydrocarbon receptor agonist indicated for the treatment of plaque psoriasis in adults and atopic dermatitis in adults and pediatric patients ≥2 years. It is applied topically and is managed under pharmacy prior authorization rules in this policy.

For both indications this policy requires prior documentation of diagnosis and prior topical therapy trials appropriate to disease severity before initial approval. For plaque psoriasis a minimum 4-week trial and failure, contraindication, or intolerance to one of the specified topical therapies (for example: corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, coal tar) is required. For atopic dermatitis a history of failure, contraindication, or intolerance to appropriate topical therapy per severity is required (mild disease: any-potency topical corticosteroid; moderate disease: medium- to high-potency topical corticosteroid; or one topical calcineurin inhibitor). Authorization for covered uses is issued for 12 months when criteria are met.

Policy Revision History

12/2024annual_review

Annual review: removed prescriber requirement and updated initial authorization to 12 months.

11/2023annual_review

Annual review: updated policy to prohibit use in combination with targeted immunomodulators and simplified reauthorization criteria to require documentation of positive clinical response and absence of combination therapy.

5/2025material_change_added_indicationLatest

Added coverage criteria for atopic dermatitis with specified topical therapy trial requirements.